Drug intelligence / Profile preview

AU-105

Development stage: Preclinical
Lead developer: Aurora Biopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

**AU-105** is a HER2-targeted CAR-T immunotherapy in development by Aurora BioPharma for oncology indications. It modulates HER2 and incorporates T lymphocyte replacements, functioning as a chimeric antigen receptor T-cell therapy designed to target HER2-expressing cancer cells, potentially offering enhanced efficacy against solid tumors through engineered T-cell activation and tumor cell lysis.[1][5][13]

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on AU-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AU-105.

Explore the full profile